<DOC>
	<DOCNO>NCT01928082</DOCNO>
	<brief_summary>The purpose study assess estrogen replacement normalize urinary calcium excretion postmenopausal woman hypercalciuria low bone mass ass difference response estrogen replacement woman familial hypercalciuria compare nonfamilial hypercalciuria .</brief_summary>
	<brief_title>The Effects Estrogen Replacement Therapy Postmenopausal Women With Hypercalciuria Low Bone Mass</brief_title>
	<detailed_description>Subjects primarily recruit subject protocol 12-1421 . Subjects may also identify chart review patient see Dr. Favus Bone Clinic University Chicago . These subject mail letter describe study request contact u willing participate study . We plan enroll 20 subject obtain complete data 16 subject . We aim 10 subject confirm familial idiopathic hypercalciuria ( IH ) 10 subject family history hypercalciuria . Subjects bring Clinical Research Center University Chicago blood sample collect phlebotomy obtain follow screen test : complete metabolic panel ; include calcium , phosphate , magnesium , creatinine , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , albumin ; parathyroid hormone , 25-hydroxyvitamin D , follicle stimulate hormone ( FSH ) , estradiol . A twenty-four hour urine collection start second void day collect calcium , phosphate , magnesium , citrate , oxalate , sodium , ammonia , sulfate , creatinine . Subjects diuretic screen 2 week washout period , provide discontinue safely . If subject participate study protocol number 12-1421 , screen test repeat result protocol number 12-1421 used determine eligibility . Screening subject meet inclusion criterion proceed observational study . Screening subject vitamin D deplete ( serum 25-hydroxyvitamin D le 35 ng/mL ) may rescreened repletion vitamin D. A letter describe study aim , protocol , risk benefit send primary care physician gynecologist . Upon completion study , summary letter send well . Prior baseline visit twenty-four hour urine collection start second void day collect calcium , phosphate , magnesium , citrate , oxalate , sodium , ammonia , sulfate , creatinine . Subjects diuretic require 2 week washout period , provide discontinue safely . During baseline visit medical history take physical exam perform . Venous blood collect 1,25-dihydroxyvitamin D3 , osteocalcin , bone-specific alkaline phosphatase , C-telopeptides type 1 collagen ( CTX ) , procollagen type 1 N-terminal propeptide ( P1NP ) , bone morphogenetic protein 2 ( BMP-2 ) , sclerostin . If subject blood test perform precede four month protocol 12-1421 , blood test repeat . 18F sodium fluoride PET/CT bone scan perform . The protocol radionuclide image attach . All subject start transdermal 17-beta-estradiol 0.05 mg/d , equivalent standard dose conjugate estrogen dose 0.625 mg , 4 week increase 0.1 mg subsequent 4 week . Given short duration study , progesterone provide , 8 week sufficient duration significantly increase risk endometrial cancer ( Strom , Schinnar et al . 2006 ) . For entire study , diuretic discontinue deem safe principle investigator prescribe physician . Throughout study , subject maintain 900-1200 mg dietary calcium daily . To monitor dietary calcium intake , 5 day diet diary keep Sunday Thursday fourth week medication dose . Compliance study medication assess estrogen patch count . The following blood test repeat 4 8 week start estradiol patch : complete metabolic panel ( include calcium , phosphate , potassium , bicarbonate , chloride , magnesium , creatinine , albumin ) , 25-hydroxyvitamin D , 1,25-dihydroxyvitamin D3 , parathyroid hormone , estradiol , osteocalcin , bone-specific alkaline phosphatase , C-telopeptides type 1 collagen ( CTX ) , procollagen type 1 N-terminal propeptide ( P1NP ) , bone morphogenetic protein 2 ( BMP-2 ) , sclerostin . In addition , 4 8 week start estradiol patch , 24 hour urine collection perform calcium , phosphate , magnesium , citrate , oxalate , sodium , ammonia , sulfate , creatinine .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Hypercalciuria</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Postmenopausal woman Diagnosis hypercalciuria Diagnosis low bone mass Vitamin D replete ( serum 25hydroxyvitamin D level &gt; 35 ng/mL ) Secondary cause hypercalciuria ( primary hyperparathyroidism , sarcoidosis , vitamin D excess , malignant neoplasm , renal tubular acidosis ) Other metabolic bone disease ( primary hyperparathyroidism , hyperthyroidism , hypercortisolemia , severe gastrointestinal disorder , liver cirrhosis , renal failure ( Cr &gt; 1.5 ) , active malignancy include multiple myeloma , rheumatological disease , Paget 's disease bone ) Use medication affect bone calcium metabolism ( corticosteroid previous 3 month , suppressive dose thyroid hormone , calcium channel blocker , anticonvulsant , aromatase inhibitor , thiazolidinediones , cyclosporine A ) History coronary artery disease Breast cancer suspect estrogendependent neoplasia Previous venous thromboembolic event Stroke Active liver disease Tobacco use within past 6 month Negative colonoscopy within previous 10 year sigmoidoscopy within previous 5 year Negative mammogram within previous 2 year Negative Pap smear within previous 3 year woman &lt; = 65 year old intact cervix No vaginal bleeding within prior 5 month . Age &gt; = 70 &gt; = 20 year since last menstrual period use hormone replacement therapy</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hypercalciuria , Familial Idiopathic</keyword>
	<keyword>Hypercalciuria</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Postmenopausal woman</keyword>
</DOC>